QUICK SPARK: Capricor Stock Dives — 'Complete Fraud' Says Pharma Bro Martin Shkreli

‘Pharma Bro’ Martin Shkreli is publicly accusing Capricor Therapeutics (NASDAQ:CAPR) of fraud and alleging legal action will be taken against its CEO and a consultant over patient data.

Shkreli posted on X that “$CAPR is a complete fraud” and later wrote in a separate post that “charges will be brought” on Capricor CEO Linda Marbán and statistics consultant Suzanne Hendrix, claiming they were “playing with patient data.”

Benzinga has reached out to Capricor Therapeutics for comment and will update this story with any response.

the $CAPR is a complete fraud pic.twitter.com/rj9dm1nX3Z

— Martin Shkreli (@MartinShkreli) July 27, 2026

charges will be brought on $CAPR CEO @linda_marban & statistics consultant Suzanne Hendrix. having been myself, i am loathe to recommend prison. in this case, i'm making sure you're both going. playing with patient data is a line you cannot cross. in my worst hour i'd never.

— Martin Shkreli (@MartinShkreli) July 27, 2026

FDA Documents Raise Concerns

Capricor’s stock has been under pressure following the release of FDA briefing documents that questioned the effectiveness of its Duchenne cell therapy. 

On Monday, shares of Capricor plummeted over 60% after the FDA posted these documents ahead of a July 29 advisory committee meeting.

The documents suggested that the data from Capricor’s pivotal HOPE-3 study might not meet the FDA’s standard for substantial evidence of effectiveness, as it relies on a single pivotal Phase 3 trial. This has led to significant weakness in Capricor’s stock.

Legal Dispute with NS Pharma

Adding to Capricor’s challenges, the company has filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary NS Pharma. The dispute centers on the distribution agreement for Deramiocel, Capricor’s investigational cell therapy for Duchenne muscular dystrophy.

Capricor alleges that the agreement’s pricing terms could limit patient access to the therapy, particularly for those covered by Medicare, Medicaid, and private insurance plans.

The company is seeking to revise the pricing mechanism to ensure broader access, as detailed in a May 8 report.

Technical Analysis

Capricor Therapeutics has experienced a significant decline, losing about $721.59 million in market cap over approximately three sessions. The stock is trading at $7.24, well below its 50-day and 200-day moving averages of $24.99 and $23.32, respectively. Additionally, Capricor’s RSI(14) stands at 13.51, indicating an oversold condition.

CAPR Stock Price Activity: Capricor Therapeutics shares were down 67.51% at $6.40 at the time of publication on Monday, according to Benzinga Pro data.

Image: Shutterstock